A trial looking at RO5126766 for solid tumours and myeloma

Cancer type:

All cancer types




Phase 1

This trial is looking at a new drug called RO5126766 to treat solid tumours and a type of cancer called myeloma. It is for people with a solid tumour Open a glossary itemor myeloma who have no standard treatment Open a glossary item options available to them.

Researchers are looking for new drugs that will help people whose cancer is getting worse despite having treatment. In this trial, they are looking at a drug called RO5126766.

RO5126766 is a type of drug called a cancer growth blocker.  It targets 2 proteins that normally send signals to cells telling them to divide and grow. RO5126766 works by blocking the action of these proteins and hopefully causing the cancer to shrink or stop growing.

The aims of this trial are to

  • Find out how often people should have RO5126766 (twice a week, or 3 times a week)
  • Learn more about the side effects of this drug and how best to reduce these side effects
  • See what happens to RO5126766 in the body

Who can enter

You may be able to join this trial if all of the following apply.

  • You have a solid tumour Open a glossary item or myeloma that has come back despite having standard treatment Open a glossary item, or there isn't a standard treatment available and if you have a solid tumour you have at least one area of cancer that can be measured or monitored
  • You have satisfactory blood test results
  • You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
  • If you have a solid tumour, a sample of your cancer that was removed when you had surgery or a biopsy Open a glossary item is available for the trial team to test. If you have myeloma, a sample of bone marrow Open a glossary item is available for testing
  • Your cancer cells have a change (mutation Open a glossary item) in genes called BRAF, KRAS or NRAS (the trial team will test for this)
  • You are willing to use reliable contraception for 4 weeks before the trial, during treatment and for 6 months afterwards if there is any chance that you or your partner could become pregnant
  • You are at least 18 years old

You cannot join this trial if any of these apply. You

  • Have cancer that has spread to your brain
  • Have had chemotherapy in the last 4 weeks (or in the last 6 weeks if you had a chemotherapy drug called a nitosourea Open a glossary item or a drug called mitomycin C)
  • Have had biological therapy or treatment on a trial in the last 4 weeks (you may still be able to take part if you are in an observational study)
  • Have had radiotherapy in the last 4 weeks, unless it was for symptom control only
  • Have had hormone therapy in the last 2 weeks (with the exception of some men with prostate cancer)
  • Are still having serious side effects from any anti cancer treatment
  • Have had major surgery to your chest or stomach and you have not yet fully recovered
  • Are known to be HIV, hepatitis B or hepatitis C positive
  • Have certain heart problems (the trial team can advise you about this)
  • Have any other medical condition that the trial doctor thinks could affect your taking part
  • Have taken other medication in the last 7 days that affects body substances called CYP enzymes (your doctor can advise you about this)

Trial design

This is a phase 1 trial. The researchers need about 38 people to take part.

The trial is in 2 parts. The first part has finished and people are now joining the second part.

In part 1, people taking part had RO5126766 either

  • Twice a week (Monday and Thursday) or
  • 3 times a week (Monday, Wednesday and Friday)

How often they had it depended on when they joined the trial.

In part 2, everyone has RO5126766 twice a week on Monday and Thursday. This was found to be the best schedule in the first part of the trial. The trial team will explain exactly how and when to take RO5126766.

You have RO5126766 as a capsule after a light meal and at least 1 hour before your next meal. Swallow the capsule whole, do not crush or chew it.

If at any point your cancer starts to get worse, or you have serious side effects, you will stop the trial treatment. Your doctor will discuss whether there are other treatment options for you.

If it is helping, you may have RO5126766 for at least a year. After a year, the trial doctor will discuss whether it would be a good idea to continue treatment with RO5126766.

Hospital visits

You will see the doctors and have some tests to help them decide if you are able to take part in the trial. This may involve more than one hospital appointment. The tests include

  • Blood tests
  • Physical examination including an eye examination
  • Tests to find out how well your liver and kidneys are working
  • CT scan or MRI scan of your chest, stomach and pelvis Open a glossary item
  • Heart trace (ECG Open a glossary item)
  • Heart scan (echocardiogram Open a glossary item or MUGA scan Open a glossary item)

On the first day of your treatment you stay in hospital for 2 nights so that you can have regular blood tests. You have blood tests on 9 different occasions over 2 days. The blood tests look at how much of the drug is in your blood and the effect it is having on your body.

You stay in hospital for 2 nights to have these blood tests again 3 weeks later. You won’t have to stay overnight in hospital for any of your other treatments.

You go to hospital on the first day of every week for 2 months. You have RO5126766 at hospital on these days. After 2 months, you may only need to go to hospital every 2 weeks. After a further 2 months you may only need to visit hospital every month. At these appointments you see a doctor and have blood tests. You have an eye examination once a month for 2 months, then every 2 months after that.

You have a heart scan at the start of the second month of treatment. You have a CT scan or MRI scan every 2 months during treatment. You may also have blood tests to test for tumour markers Open a glossary itemto see how well the treatment is working.

You go to hospital about 1 month after you finish treatment and you may have some of the above tests repeated. If you have any side effects, the trial team will keep in touch with you until these get better. This may be at a hospital appointment or over the phone if you can't get to hospital.

Side effects

As RO5126766 is a new drug, there may be side effects we don’t know about yet. Possible side effects include

While some of these side effects may get worse during the first few doses of RO5126766, it is possible that some side effects will become less as treatment continues.



Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Udai Banerji

Supported by

Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research (ICR)
Royal Marsden NHS Foundation Trust

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page